Ibragimova, Khava I. E.
Geurts, Sandra M. E.
Meegdes, Marissa
Erdkamp, Frans
Heijns, Joan B.
Tol, Jolien
Vriens, Birgit E. P. J.
Dercksen, Marcus W.
Aaldering, Kirsten N. A.
Pepels, Manon J. A. E.
van de Winkel, Linda
Peters, Natascha A. J. B.
Teeuwen-Dedroog, Nathalie J. A.
Vriens, Ingeborg J. H.
Tjan-Heijnen, Vivianne C. G. http://orcid.org/0000-0002-3935-7440
Funding for this research was provided by:
ZonMw (80-82500-98-8003)
Novartis
Roche
Pfizer
Eli Lilly and Company
Daiichi-Sankyo
Article History
Received: 17 October 2022
Accepted: 1 December 2022
First Online: 12 January 2023
Declarations
:
: Khava I.E. Ibragimova Financial interests: Grants from Novartis BV, Roche, Pfizer, Eli Lilly, Daiichi-Sankyo. Marissa Meegdes Financial interests: Grants from Novartis BV, Roche, Pfizer, Eli Lilly, Daiichi-Sankyo. Sandra M.E. Geurts Financial interests: Grants from Novartis BV, Roche, Pfizer, Eli Lilly, Daiichi-Sankyo, Gilead, Grants and personal fees from AstraZeneca. Nathalie J.A. Teeuwen-Dedroog Financial interests: Grants from Novartis BV, Roche, Pfizer, Eli Lilly, Daiichi-Sankyo. Ingeborg Vriens Financial interests: Grants from AstraZeneca and Pfizer. Vivianne C.G. Tjan-Heijnen Financial interests: Grants and personal fees from Roche, grants and personal fees from Novartis, grants and personal fees from Pfizer, grants and personal fees from Lilly, grants and personal fees from AstraZeneca, grants from Daiichi-Sankyo and grants from Gilead. All remaining authors have no relevant financial or non-financial interests to disclose. Signed by first author Khava Ibragimova on behalf of all authors.
: The Registry was approved and the need for informed consent waived by the Medical Research Ethics Committee of Maastricht University Medical Center (METC 15-4-239).